At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
AMG 986drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
In Brief
A Phase 1 clinical trial evaluating AMG 986 for Heart Failure. Completed, enrolled 12 participants across 4 sites.
Detailed Summary
A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionMar 2018
Study CompletionApr 2018
TodayJul 2026
First PostedOct 24, 2017
Enrollment StartDec 12, 2017
Primary CompletionMar 12, 2018
Study CompletionApr 5, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.7 years ago
Interventions
AMG 986drug
tablets for oral administration